ArticleFrontiers in molecular biosciences2025
Glycoprotein M6B suppresses the maintenance of glioma stem cell stemness and proliferation via the integrin β1/β-catenin pathway.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell-type-specific architecture of the hypothalamus in a socially plastic vertebrate.bioRxiv : the preprint server for biology · 2026Article
- Integrated network toxicology, bioinformatics, and molecular docking reveal the potential molecular mechanisms linking bisphenol A to glioma progression.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are highly aggressive intracranial tumors associated with poor prognosis. Glioma stem cells (GSCs) have been shown to play a pivotal role in tumor progression. Previous studies indicate that GPM6B expression correlates with glioma grade and neuronal differentiation. However, the precise mechanisms of GPM6B in glioma remain unknown. In this study, we aim to elucidate the regulatory role of GPM6B in glioma. Methods: The relationship between the expression of GPM6B and glioma was analyzed using the CGGA and TCGA databases. Western blot analysis was performed to further validate GPM6B expression in clinical samples. The interaction between GPM6B and the Wnt signaling pathway was explored using co-immunoprecipitation, mass spectrometry, quantitative real-time PCR, and Western blot. These findings were further confirmed in cells transduced with different lentiviral constructs. Tumor sphere formation and extreme limiting dilution assays were conducted to assess the stemness of glioma stem cells. Finally, the role of GPM6B in glioma progression was validated in nude mouse models. Results: The expression of GPM6B was negatively correlated with glioma grade and prognosis. GPM6B was co-localized with Integrin β1 on the cell membrane. The interaction between GPM6B and Integrin β1 inhibited the expression of β-catenin and its downstream proteins, including p-STAT3, c-Myc, and SOCS3. Moreover, SOCS3 promoted the degradation of GPM6B. Overexpression of GPM6B suppressed tumor sphere formation and reduced the sphere formation efficiency of glioma stem cells. In addition, GPM6B overexpression markedly inhibited the tumorigenic effects of β-catenin and SOCS3. These findings were confirmed Conclusion: The expression of GPM6B was negatively correlated with the grade and prognosis of glioma. GPM6B promoted the transformation of glioma stem cells and inhibited growth of glioma by suppressing Integrin β1-mediated regulation of β-catenin, while reducing its own degradation through inhibition of the ubiquitinase SOCS3, thereby stabilizing its function in glioma. Collectively, these results identify GPM6B as a critical regulator of glioma stemness and a potential therapeutic target for glioma, providing new insights into glioma biology and offering a foundation for future translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.